







Db 481 agaaaacaccaatttcgttgttttgtctctactcagaaggaaatgcaca 540  
 PI Goto M, Higashio K, Kobayashi F, Mochizuki S, Morinaga T;  
 PI Nakada N, Shimada N, Tsuda E, Ueda M, Yano K, Yasuda H;  
 DR WPI; 96-402320/40.  
 DR P-PSDB; R89932.

Db 541 caccacaaacataatgttccggaaacactgaacaaatggaaatgttacc 600  
 PT DNA encoding osteoclastogenesis inhibitory factor protein - useful  
 for bone resorption control, esp. treatment of osteoporosis  
 PT Claim 30; Page 133-134; 183P; Japanese.

Db 586 CACGACAACTATGTTCGGAACAGTGAATCACTCAAAATGTGGATAATGATGTAC 645  
 PS This sequence encodes a mutated version of the full length  
 CC Osteoclastogenesis inhibitory factor (OCIF) or the invention. This  
 sequence encodes OCIF-C20S in which the 20th CYS residue in the mature  
 CC OCIF protein is substituted by Ser. The OCIF of the invention has a  
 CC molecular weight by SDS-PAGE of 60 kD under reducing conditions and  
 CC 120 kD under non-reducing conditions. The protein is adsorbed onto  
 CC carbon-exchangers or heparin and its activity is lowered after 10 mins  
 CC at 70 deg.C or 30 mins at 56 deg.C, and is lost after 10 mins at 90  
 CC deg.C. OCIF is useful in the control of bone resorption and therefore  
 CC in the treatment and prevention of disorders of bone resorption, e.g.  
 CC osteoporosis. 1206 BP; 389 A; 283 C; 270 G; 264 T;

SO Sequence 1206 BP; 389 A; 283 C; 270 G; 264 T;

Query Match 78.6%; Score 1200; DB 27; Length 1206;  
 Best Local Similarity 99.8%; Pred. No. 0.00e+00;  
 Matches 1203; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Db 841 gtgcacggcacattggacatgtgtttccatctccatcgagcggctgtttgtgaa 900  
 QY 886 GTGCCAGGGCACATGGACACTAACCTCACCTCGAGCAGCTGTACTGTGAA 945  
 Db 901 agtttccggaaagaatggggcggaaacatggaaaaaacataaaggcggaaa 960  
 QY 946 AGCTTACCGGGAAAGAATGGGGAGGAGAACATGAAACAAACATAAGCATGAA 1005  
 Db 961 ccaggagacggatctgaactgtcgtttgtggcgataaaaatggcggaaaac 1020  
 QY 1006 CCCAGTOACCAGATCTTGAGCTGTCAGTTGTGCGGAAATAAACATGGCAGAAC 1065  
 Db 1021 accttgaaggcctaattgtggacttaaaggactcaaaaggactttcccaaact 1080  
 QY 1066 ACCTTGAAAGGCCTAATGCGACTAAAGACTCAAGAGTACCTTCCAAACT 1125  
 Db 1081 gtcactcggatctaaaggacccatcgatgttccacatgttccaaatgttcc 1140  
 QY 1126 GTCACTCAGAGCTAAAGAACATCAGTTCACAGCTCACAGTACAAATG 1185  
 Db 1141 ttcggaaatgttttagatgtggatccggccatcgatggatggatggatgg 1200  
 QY 1186 TATCAGAGTTTTAGAATGATGATGTTACCGTCATCACTAAATAAGCTG 1245  
 RESULT 4  
 :D T33162 standard; DNA; 1206 BP.  
 :C T33162;  
 :T 22-APR-1997 (first entry)  
 :E Mutated OCIF, OCIF-C20S, coding sequence; OCIF; heparin; bone resorption; Osteoclastogenesis inhibitor; OCIF; heparin; bone resorption; osteoporosis; ss.  
 :W Synthetic.  
 :H Key Location/Qualifiers  
 :T sig\_peptide 1..63  
 :T mat\_peptide 64..1203  
 :T /\*tag= b  
 :T product OCIF-C20S  
 :N W09626217-A1.  
 :D 29-AUG-1996.  
 :F 20-FEB-1995; JPO174.  
 :P 20-FEB-1995; JP-05497.  
 :R 21-JUL-1995; JP-207508.  
 :A (SNOW ) SNOW BRAND MILK PROD CO LTD.

Db 481 agaaaacaccaatttcgttgttttgtctctactcagaaggaaatgcaca 540  
 QY 541 cacacacatgttccggaaacagtgaatcaactaaatgtgaataatgttacc 600  
 QY 586 CACGACAACTATGTTCGGAACAGTGAATCACTCAAAATGTGGATAATGATGTAC 645  
 Db 601 ctggatggggatcttcgtttttgtttctcaatgtggatctttactgttacc 660  
 QY 646 CTGGTGGAGGAGATCTCAGGTTGTCGTCCTACAGTGTACAGTGTAC 705  
 Db 661 agtttccggaaatggggcggaaatggatggatggatggatggatggatgg 720  
 QY 706 AGTGTGTTGAGCATTTGCGGCGAACAGTAAACGAGAGTGGAGGATA 765  
 Db 721 aaacggcaacacagctcacaagaacagactttccagctgtgaaatcatcaa 780  
 QY 766 AACGGCAACACAGCTCAGAAGAACATCAA 825





**RESULT** 7  
**ID** T33172 standard; DNA; 1200 BP.  
**AC** T33172;  
**DT** 22-APR-1997 (first entry)  
**DE** Mutated OCIF, OCIF-CL, coding sequence.  
**KW** Osteoclastogenesis inhibitory factor; OCIF; heparin; bone resorption; osteoporosis; ss.  
**OS** Synthetic.  
**FH** Key Location/Qualifiers  
**FT** sig\_peptide 1..63  
**FT** /\*tag= a  
**FT** mat\_peptide 64..1197  
**FT** /\*tag= b  
**FT** /product= OCIF-CL  
**PN** WO9526217-A1.  
**PD** 29-AUG-1996.  
**DD** 20-FEB-1996; J00374.  
**DR** 20-FEB-1995; JP-054977.  
**DD** 21-JUL-1995; JP-207508.  
**PA** (SNOW BRAND MILK PROD CO LTD,  
**PI** Goto M, Higashio K, Kobayashi F, Mochizuki S, Moritraga T,  
**PI** Nakagawa N, Shima K, Tsuda E, Ueda M, Yano K, Yasuda H;  
**WPI** 96-402320/40.  
**DR** P-PSDB; R99942.  
**PT** DNA encoding osteoclastogenesis inhibitory factor protein - useful  
**PT** for bone resorption control, esp. treatment of osteoporosis  
**PS** Claim 60, Page 143-144; 183PP; Japanese.  
**CC** This sequence encodes a mutated version of the full length  
**CC** osteoclastogenesis inhibitory factor (OCIF) of the invention. This  
**CC** sequence encodes OCIF-CL in which amino acids 379-380 of the mature  
**CC** protein have been deleted. The OCIF of the invention has a molecular  
**CC** weight by SDS-PAGE of 60 kD under reducing conditions and 120 kD under  
**CC** non-reducing conditions. The protein is adsorbed onto cation-exchangers  
**CC** or heparin and its activity is lowered after 10 mins at 70 deg.C or 30  
**CC** mins at 55 deg.C and is lost after 10 mins at 90 deg.C. OCIF is useful  
**CC** in the control of bone resorption and therefore in the treatment and  
**CC** prevention of disorders of bone resorption, e.g. osteoporosis.  
**Sequence** 1200 BP; 387 A; 283 C; 268 G; 262 T;





acid changes have been caused by the introduction of a restriction site. The OCIF of the invention has a molecular weight by SDS-PAGE of 60 kd under reducing conditions and 120 kd under non-reducing conditions. The protein is adsorbed onto cation-exchangers or heparin and its activity is lowered after 10 mins at 70 deg C or 30 mins at 56 deg.C and is lost after 10 mins at 90 deg.C. OCIF is useful in the control of bone resorption and therefore in the treatment and prevention of disorders of bone resorption, e.g. osteoporosis.





